CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million

May 14, 2026

Bayer to acquire Perfuse Therapeutics to complement ophthalmology pipeline

May 6, 2026

TIME100 Health Honors Dr. Zhen Xu for Pioneering Work in Non-Invasive Cancer Therapy

February 13, 2026

Contego Medical Announces Unprecedented 30-day Outcomes From The PERFORMANCE III TCAR-IEP Study

November 6, 2025

HistoSonics Announces $2.25B Acquisition by Consortium of Top-Tier Investors

August 7, 2025

Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

May 23, 2025

Perfuse Therapeutics Announces Positive Results from the Completed Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma

May 7, 2025

Atsena gets Bain’s support in $150M Series C to thwart blindness with gene therapy

April 2, 2025

Atsena raises $150M for ocular gene therapies with Bain, Sofinnova in tow

April 2, 2025

Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs

January 13, 2025

Aer Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Fexlamose in Chronic Obstructive Pulmonary Disease

January 8, 2025

HistoSonics Announces Oversubscribed $102 Million Series D Financing to Scale Launch of Non-Invasive Histotripsy Platform

August 15, 2024

Endogenex™ Announces $88 Million Series C Financing to Complete Pivotal Trial of the ReCET™ System in Patients with Type 2 Diabetes

June 25, 2024

Shionogi Further Extends Infectious Disease Innovation Platform with Planned Acquisition of Qpex Biopharma, Inc.

July 25, 2023

Myeloid Therapeutics Announces $73 Million Financing to Advance mRNA-based Immunotherapy Pipeline

May 18, 2023

NewYork-Presbyterian Enrolls First Patient in National Study of Sacral Nerve Stimulation Device for Inflammatory Bowel Disease

May 3, 2023

Cardiosense, Inc., Completes $15.1 Million Series A Financing to Advance Artificial Intelligence Platform for Heart Disease

December 8, 2022

Teleflex to Expand Its Surgical Portfolio with Differentiated Stapling Technology for Bariatric Surgery

September 19, 2022

Qvella FAST System and FAST-PBC Prep Cartridge Get CE Marked and FDA Listed for In Vitro Diagnostic Use

April 25, 2022

Huma.AI Adds Post-Market Surveillance Capacity to its Unique AI-Based Healthcare Data Knowledge Platform

February 7, 2022

Aledade Acquires Advance Care Planning Company Iris Healthcare as Part of New Health Services Arm

January 25, 2022

VIGIL NEUROSCIENCE ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING

January 7, 2022

Tune Therapeutics Debuts with $40 Million to Fine-Tune the Human Genome

December 3, 2021

Morgan Stanley Expansion Capital and Ally Bridge Group Lead $135 Million Investment in Elligo

September 23, 2021

Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases

August 18, 2021

CVRx, Inc. Announces Upsized Pricing of Initial Public Offering

June 30, 2021

RapidPulse Launches With $15 Million Series A Financing for Ischemic Stroke Therapy

June 23, 2021

Veralox Therapeutics Announces Closing Of $16.6 Million Series A Financing And Announces New Board Members

June 16, 2021

Standard Bariatrics Secures $35M in Series B Funding to Accelerate Development and Commercialization of Their First Bariatric Surgical Platform for Sleeve Gastrectomy

June 1, 2021

CROs dMed and Clinipace Merge to Accelerate Customer Success

April 28, 2021

Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics

March 2, 2021

FDA approves G1 Therapeutics’ COSELA™ (TRILACICLIB): The first and only myeloprotection therapy to decrease the incidence of chemotherapy-induced myelosuppression

February 18, 2021

Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists

February 18, 2021

BIAL Goes Global with New US Research Center and Acquisition of Promising Parkinson’s Disease Programs

October 1, 2020

Kymera Therapeutics Announces Pricing of Upsized Initial Public Offering

August 21, 2020

Trefoil Therapeutics Begins First Clinical Trial of Regenerative Treatment for Patients with Corneal Endothelial Dystrophies

August 19, 2020

Atsena Therapeutics acquires exclusive rights to Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis

August 14, 2020

Kymera Therapeutics and Sanofi Enter into Strategic Partnership to Advance Novel Protein Degrader Therapies to Patients

July 9, 2020

Shattuck Labs Announces Closing of $118 Million Series B Financing

June 15, 2020

PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients

May 27, 2020

AtaCor Medical Secures $25M Financing to Continue Extracardiac Pacing Development

April 28, 2020

Nature Communications Highlights Research by Scientists at Graybug Vision and Johns Hopkins University on Sustained Treatment of Retinal Diseases

April 23, 2020

Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform

March 12, 2020

HealthStream Acquires NurseGrid, #1 Rated and Top Downloaded App for Nurses

March 12, 2020

Graybug Vision Presents Preclinical Results for GB-401, a Potential Sustained-Delivery Treatment of up to Six Months for Primary Open Angle Glaucoma, at the American Glaucoma Society Annual Meeting

February 28, 2020

PhaseBio Announces European Regulatory Update for PB2452

February 11, 2020

Trefoil Therapeutics Appoints Thomas M. Tremblay, RN BSN, Vice President, Clinical Development

February 10, 2020

PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452

January 10, 2020

BioSpace.com selects Qpex to be among Top Life Science Companies to Watch in 2020

January 6, 2020

HistoSonics Robotic Sonic Beam Therapy Platform Wins 2019 Frost & Sullivan Innovation Award

January 6, 2020

Alkermes to Acquire Rodin Therapeutics

November 18, 2019

Sarepta pays StrideBio $48M for preclinical gene therapies

November 15, 2019

NextGen Healthcare Announces Agreement to Acquire Medfusion, Inc.

November 13, 2019

Clearside Biomedical Announces Option Exercise by REGENXBIO for Global License for Use of SCS Microinjector™ in AAV Gene Therapy Delivery

October 30, 2019

410 Medical Secures $8 Million in Series A Financing, Expands Board of Directors

October 22, 2019

Qpex Biopharma and Brii Biosciences Enter Into a Strategic Collaboration to Develop and Commercialize Antibiotics for Drug-Resistant Infections in China

October 22, 2019

A twisty career path to improve care for smokers

October 11, 2019

Graybug Vision Initiates Phase 2b (ALTISSIMO) Clinical Trial of GB-102 in Patients with Wet Age-Related Macular Degeneration

October 4, 2019

VERTEX AND RIBOMETRIX ESTABLISH STRATEGIC COLLABORATION TO DISCOVER AND DEVELOP RNA-TARGETED SMALL MOLECULE THERAPEUTICS

September 30, 2019

Graybug Vision Initiates Clinical Trial in Macular Edema Secondary to Diabetic Macular Edema or Retinal Vein Occlusion

September 18, 2019

Graybug Vision Secures $80 million of Additional Funding to Advance its Potentially Transformative Retina and Glaucoma Clinical Programs

August 20, 2019

GeneCentric Therapeutics Acquires Select ImmunoGenomics

August 20, 2019

Trefoil Therapeutics Raises $28 Million Series A to Advance Engineered FGF-1 for the Treatment of Corneal Diseases

July 16, 2019

G1 Therapeutics Announces Updated Results from Phase 2 Trial of Trilaciclib in Combination with Chemotherapy Showed Statistically Significant Improvement in Overall Survival in Women with Metastatic Triple-Negative Breast Cancer

June 18, 2019

Qpex Biopharma to Provide First Public Presentations of Preclinical Data on the Novel Ultra-Broad-Spectrum Beta-lactamase Inhibitor QPX7728 for IV and Oral Products at 2019 ASM Microbe Meeting

June 13, 2019

Artizan Biosciences Announces Corporate Progress and Financing

June 11, 2019

Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases

May 15, 2019

Elligo Health Research Raises $20M to Connect More Physicians and Their Patients to Clinical Research as a Care Option

May 7, 2019

Qpex Biopharma Licenses Polymyxin Antimicrobial Program from Monash University to Address Drug-Resistant Infections

April 30, 2019

G1 Therapeutics Announces Positive Feedback from Trilaciclib End-of-Phase 2 Meeting with FDA; Expects to File NDA in 2020

April 30, 2019

HistoSonics, Non-Invasive Robotics Pioneer, Closes $54 Million Series C Financing Breakthrough medical platform offers vision of personalized tumor treatments with its novel sonic beam therapy

April 9, 2019

StrideBio and Takeda Sign Collaboration and License Agreement to Advance Novel Gene Therapies for Neurological Diseases

March 28, 2019

Full Results from PhaseBio Phase 1 Clinical Trial of PB2452 Published in the New England Journal of Medicine and Presented at the American College of Cardiology’s 68th Annual Scientific Session

March 18, 2019

Mycovia Pharmaceuticals Initiates Additional Phase 3 Clinical Study Evaluating VT-1161 for the Treatment of Vulvovaginal Candidiasis

February 27, 2019

Graybug Vision Appoints Frédéric Guerard as Chief Executive Officer Pharmaceutical Industry Veteran and Former Worldwide Business Franchise Head of Ophthalmology at Novartis

February 5, 2019

Standard Bariatrics Names Kurt Azarbarzin as Chairman of the Board of Directors

January 30, 2019

HistoSonics Selected as One of the Hottest Startups at the 2019 J.P. Morgan Healthcare Investment Conference

January 8, 2019

Ribometrix raises $30M to drug upstream RNA with small molecules

November 13, 2018

Kymera Therapeutics Announces $65 Million Series B Financing to Advance Pipeline of Targeted Protein Degraders in Oncology and Immunology

November 13, 2018

Qpex Biopharma Announces Closing of $33 Million Series A Financing and Launch of Company to Address Worldwide Problem of Drug-Resistant Infections

October 25, 2018

Clearside Biomedical Appoints Thomas A. Ciulla, M.D., MBA as Chief Medical Officer

October 25, 2018

G1 Therapeutics to Present Additional Data from Randomized Phase 2 Trial of Trilaciclib in Combination with Etoposide/Carboplatin at European Society for Medical Oncology (ESMO) 2018 Congress

October 22, 2018

G1 Therapeutics Expands Executive Leadership Team with Appointment of John Demaree as Chief Commercial Officer and Stillman Hanson as General Counsel

July 9, 2018

Standard Bariatrics closes Series A round of financing

April 18, 2018

Elligo Health Research Raises $16M to Improve Access to Clinical Trials

March 20, 2018

Wildflower Health Receives $8 Million Capital Investment in Funding Round Led by Health Enterprise Partners

March 13, 2018

Clearside Announces Pricing of Public Offering of Common Stock

March 7, 2018

G1 Therapeutics Announces Pricing of Offering of Common Stock

March 7, 2018

Press Ganey Expands Real-Time Data Collection Capabilities Through Acquisition of Bivarus

January 16, 2018

Qvella Raises US$20M in Series B Financing to Fund Clinical Trials, On-going Research, Team Expansion, and Manufacturing Buildup

December 4, 2017

G1 Therapeutics and AstraZeneca Enter Clinical Trial Collaboration in Non-Small Cell Lung Cancer

November 28, 2017

Ribometrix Raises $7.5 Million in Seed Funding to Advance Platform for Discovering and Developing Small Molecule Modulators of RNA to Treat Human Diseases

October 31, 2017

Rodin Therapeutics Advances Synaptic Resilience Strategy With $27 Million In Financing And Expands Board Of Directors

September 18, 2017

Veritas Genetics Acquires Curoverse to Deploy Large-Scale Artificial Intelligence and Machine Learning in Genomics

August 4, 2017

HistoSonics Technology’s Exciting Preclinical Results to be Presented at the World Conference on Interventional Oncology (WCIO) 2017

June 7, 2017

G1 Therapeutics to Present Clinical Data on CDK4/6 Inhibitor Trilaciclib at the 2017 American Society of Clinical Oncology Annual Meeting

May 30, 2017

G1 Therapeutics Announces Pricing of Initial Public Offering

May 16, 2017

NeuroTronik Announces $23.1 Million Series B Preferred Stock Financing

April 18, 2017

Bivarus Raises $4 Million to Fuel Continued Growth

March 24, 2017

Viamet Reports Positive Results from REVIVE Phase 2b Trial of Oral VT-1161 in Recurrent Vulvovaginal Candidiasis

January 18, 2017

Viamet Reports Positive Results from RENOVATE Phase 2b Trial of Oral VT-1161 in Onychomycosis

January 6, 2017

Viamet Reports Positive Results from REVIVE Phase 2b Trial of Oral VT-1161 in Recurrent Vulvovaginal Candidiasis

January 6, 2017

G1 Therapeutics to Evaluate Trilaciclib (G1T28) in Combination with Immune Checkpoint Inhibitor in Small-Cell Lung Cancer

December 5, 2016

Medfusion Named Inaugural Member of GE Healthcare Centricity Partner Program

October 4, 2016

Tumor Ablation Expert Dr. Fred Lee, Jr. Joins HistoSonics as Board Member, Senior Medical Advisor

September 14, 2016

Spyryx Biosciences Expands Executive Team, Appoints Pulmonary Industry Leader, Alistair Wheeler, MD, MFPM as Chief Medical Officer

August 23, 2016

Clearside Biomedical, Inc. Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion

July 27, 2016

Graybug Vision Expands Executive Team with Appointments of Charles P. Semba, MD, and Ward M. Peterson, PhD

June 22, 2016

Clearside Biomedical, Inc. Announces Pricing of Initial Public Offering

June 2, 2016

G1 Therapeutics Secures $47 Million Series C Financing

May 11, 2016

Graybug Vision Announces $44.5 Million Series B Financing

May 6, 2016

Just Download It: Wyoming Discovers Novel Way to Help Pregnant Mothers

May 6, 2016

Clearside Biomedical, Inc. Announces Positive Preliminary Phase 2 Results in Patients with Macular Edema Associated with Retinal Vein Occlusion

April 26, 2016

Bivarus Raises $2 Million to Fuel Expansion Following Strong Growth in 2015

March 24, 2016

Medfusion Announces Latest Version of Medfusion Plus at HIMSS16

March 2, 2016

Improving Odds for Women in Tech? Take Notes from Biotech

February 5, 2016

Clearside Biomedical, Inc. Announces Positive Topline Data from Phase 2 Clinical Trial for the Treatment of Macular Edema Associated with Non-Infectious Uveitis

January 8, 2016

ORIG3N™ Closes $12.5 Million in Funding Lead by Hatteras Venture Partners and Syno Capital

December 17, 2015

Clearside Biomedical, Inc. Completes $20 Million Series C Financing

December 17, 2015

5 Mission-Driven Companies That Are Changing The World

December 4, 2015

Startup Qvella gets $20M Series A to develop rapid pathogen detection test

October 29, 2015

Patient engagement platform Medfusion reels in $3 million

September 1, 2015

G1 Therapeutics Announces Initiation of Two Phase 1b/2a Trials of CDK4/6 Inhibitor G1T28 in Small-Cell Lung Cancer

August 11, 2015

Aerie Pharmaceuticals and GrayBug Announce Research Collaboration Focused on Novel Delivery Technologies for Aerie Product Candidates

August 6, 2015

Wildflower Health secures $5 million in financing to expand mobile, enterprise platform for maternity and family health

June 30, 2015

ORIG3N™ Announces Strategic Collaboration with LabCorp

May 19, 2015

NuSirt Biopharma Raises $6 Million in Series C Funding

May 18, 2015

Spyryx Biosciences Secures $18 Million in Series A Financing

May 7, 2015

Clearside Biomedical, Inc. and Santen, Inc. Announce Research Collaboration in Glaucoma

May 4, 2015

Spark Therapeutics and Clearside Biomedical Announce Exclusive Option to License Technology for Potentially Differentiated Delivery of Gene Therapy to the Eye

April 29, 2015

Contego Medical Closes $5.6 Million in Series B Funding

April 20, 2015

GrayBug to Participate in 7th Ocular Diseases Drug Discovery Conference

March 17, 2015

PhaseBio Raises $40 Million Series C Financing Led By AstraZeneca

March 12, 2015

GrayBug Raises $1.74 Million in Series A2 Financing

March 10, 2015

ORIG3N™ Closes $3.1 Million in Funding Lead by Hatteras Venture Partners

February 13, 2015

Lysosomal Therapeutics Inc. Raises $20 Million in Series A Financing

February 9, 2015

G1 Therapeutics Raises $33 Million in Series B Financing

February 5, 2015

G1 Therapeutics to Present at 17th Annual BIO CEO & Investor Conference

February 2, 2015

Clearside Biomedical, Inc. Announces Ongoing Results in Phase 1/2 Clinical Trial in Patients with Non-infectious Uveitis

October 15, 2014

Clearside Biomedical, Inc. Completes $16 Million Series B Financing

September 18, 2014

G1 Therapeutics Initiates Phase 1 Clinical Trial of G1T28-1

September 18, 2014

Clearside Biomedical, Inc. Completes $16 Million Series B Financing

September 4, 2014

Edison Partners Announces Investment in Clinverse, Inc.

August 19, 2014

G1 Therapeutics Completes Leadership Team with Appointment of Raj Malik, MD, Chief Medical Officer and Greg Mossinghoff, Chief Business Officer

June 17, 2014

G1 Therapeutics Appoints Dr. Mark Velleca as Chief Executive Officer

May 20, 2014

Lysosomal Therapeutics Inc. Receives $4.8 Million in Seed Funding

May 14, 2014

Clinipace becomes a ‘preferred provider,’ starts acting like a big CRO

April 21, 2014

Clinipace Worldwide Expands into Asia with Acquisition of Choice Pharma

March 12, 2014

Industry veteran and oncologist Dr. Seth Rudnick joins G1 Therapeutics as Executive Chairman

January 7, 2014

Harvard-Spun Curoverse Raises $1.5M to Build Biomedical Big Data Platform

December 19, 2013

G1 Therapeutics to Present at Southeast BIO Investor & Partnering Forum

November 14, 2013

G1 Therapeutics Raises $12.5M Series A Financing Led by MedImmune Ventures

October 16, 2013

Molecular diagnostics company GeneCentric collects $2.5 million for cancer tests

July 12, 2013

Santen Pharmaceuticals and Clearside Biomedical Announce Financing and Research Collaboration for Posterior Ocular Disease

January 31, 2013

SBA Licenses First Fund In Early Stage Capital Initiative

January 7, 2013

Clearside Biomedical Announces First Successful Human Dosing in a Safety and Tolerability Study in Patients with Retinal Disease

November 6, 2012

Coferon, Inc. Announces $12 Million Series B Financing

July 16, 2012

Clinverse Receives $3.8 Million to Expand Its Financial Technology for Clinical Trials

May 7, 2012

Clearside Biomedical Launched With Pipeline and Technology Focused on Drugs Delivered to the Back of the Eye

January 5, 2012

PhaseBio Pharmaceuticals Announces Positive Clinical Results with its Once Weekly GLP-1 analogue, Glymera for the Treatment of Hyperglycemia in Patients with Type 2 Diabetes

November 15, 2011

Morgan Stanley Expansion Capital Leads Series C Funding in Clinipace Worldwide

September 27, 2011

PerkinElmer Signs Agreement to Acquire CambridgeSoft Corporation and Completes Purchase of ArtusLabs, Inc.

March 24, 2011

Edwards Lifesciences Acquires Embrella Cardiovascular, Inc.

March 11, 2011

Viamet Pharmaceuticals, Dow AgroSciences to Collaborate on Development of Improved Crop Protection Products

November 2, 2010

Boston Scientific to Acquire Asthmatx

September 20, 2010

Inc. Magazine Names Clinipace Worldwide to the Inc. 500 Annual List of America’s Fastest-Growing Private Companies

August 24, 2010

Viamet, Novartis Fund Targeting Metalloenzymes in $200M Deal

February 23, 2010

HistoSonics, Inc. Announces Series A Financing

January 4, 2010

Clinipace Acquires Worldwide Clinical Research, Inc. – Company Expands to Enhance its Global Clinical Operations Capabilities and Therapeutic Practice Areas

November 9, 2009

Creating A Medical Device On The (Relatively) Cheap

August 31, 2009

Embrella Cardiovascular, Inc. Announces Final Closing of Series B Round

August 14, 2009

SpineAlign Medical Treats First Patient in U.S. with New, Innovative System for Vertebral Compression Fracture Repair

July 23, 2009

Viamet Pharmaceuticals Secures $18M Financing

July 7, 2009

Pathfinder Hires Medical Device Veteran as CEO

March 11, 2009

Pathfinder Lands $5 Million Series A Round

October 30, 2008

Craig Rosen, Biopharmaceutical Development Expert, Joins Phase Bioscience as Executive Chairman

October 9, 2008

SpineWorks Medical, Inc. Announces CE-Mark for SpineAlign Vertebral Body Replacement System

July 15, 2008

Leading Protein Engineering Executive Joins Phase Bioscience as CEO

April 15, 2008

Clinipace Raises $2.6 Million Series B

January 17, 2008

Phase Bioscience Announces Series B Investment from Johnson & Johnson Development Corporation, Fletcher Spaght Ventures and Hatteras Venture Partners

October 24, 2007

Viamet Pharmaceuticals Raises $4 Million Round of Financing

June 7, 2007